Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43857   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Multicenter, Randomized, Double-blind Trial of Brexpiprazole versus Placebo for the Acute Treatment of Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder

    Summary
    EudraCT number
    		 2017-002222-20
    Trial protocol
    		 BG   PL  
    Global end of trial date
    02 Jan 2019

    Results information
    Results version number
    		 v2(current)
    This version publication date
    29 Feb 2020
    First version publication date
    29 Dec 2019
    Other versions
    		 v1
    Version creation reason
    • Correction of full data set
    Update for alignment with revised clinicaltrials.gov results posting

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    331-201-00080
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 NCT03259555
    WHO universal trial number (UTN)
    		 -
    Sponsors
    Sponsor organisation name
    Otsuka Pharmaceutical Development & Commercialization, Inc.
    Sponsor organisation address
    2440 Research Boulevard, Rockville, Maryland, United States, 20850
    Public contact
    Global Clinical Development, Otsuka Pharmaceutical Development & Commercialization, Inc., 609 524-6788, clinicaltransparency@otsuka-us.com
    Scientific contact
    Global Clinical Development, Otsuka Pharmaceutical Development & Commercialization, Inc., 609 524-6788, clinicaltransparency@otsuka-us.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    10 Jul 2019
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    02 Jan 2019
    Global end of trial reached?
    Yes
    Global end of trial date
    02 Jan 2019
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To demonstrate the efficacy of brexpiprazole for the acute treatment of manic episodes, with or without mixed features, in participants with a diagnosis of bipolar I disorder.
    Protection of trial subjects
    This study was conducted in accordance with International Council on Harmonisation (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the countries in which the study was conducted.
    Background therapy
    		 -
    Evidence for comparator
    		 -
    Actual start date of recruitment
    14 Sep 2017
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Bulgaria: 54
    Country: Number of subjects enrolled
    Poland: 24
    Country: Number of subjects enrolled
    Serbia: 32
    Country: Number of subjects enrolled
    United States: 212
    Worldwide total number of subjects
    322
    EEA total number of subjects
    78
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    321
    From 65 to 84 years
    1
    85 years and over
    0

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 -

    Pre-assignment
    Screening details
    		 The trial population consisted of adult participants (18 to 65 years) diagnosed with bipolar I disorder displaying an acute manic episode with or without mixed features requiring hospitalization.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    		 Yes
    Allocation method
    Randomised - controlled
    Blinding used
    		 Double blind
    Roles blinded
    		 Subject, Investigator

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 Brexpiprazole
    Arm description
    		 Brexpiprazole was administered orally with flexible dosing from 2 to 4 milligrams (mg)/day; titrated to a maximum of 4 mg/day.
    Arm type
    		 Experimental

    Investigational medicinal product name
    Brexpiprazole
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Starting dose of 2 mg/day; titrated to a maximum of 4 mg/day. Adjustments could be made to dosing. Treatment duration was 3 weeks.

    Arm title
    		 Placebo
    Arm description
    		 Matching placebo was administered orally in the same way as brexpiprazole to maintain the blind.
    Arm type
    		 Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Tablet taken daily for 3 weeks.

    Number of subjects in period 1
    		Brexpiprazole Placebo
    Started
    158
    164
    Received At Least 1 Dose of Study Drug
    158
    163
    Completed
    124
    134
    Not completed
    34
    30
         Consent withdrawn by subject
    19
    16
         Physician decision
    1
    2
         Adverse event, non-fatal
    6
    4
         Other
    1
    -
         Progressive Disease
    -
    2
         Non-Compliance With Study Drug
    1
    -
         Lost to follow-up
    -
    2
         Lack of efficacy
    6
    4

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Brexpiprazole
    Reporting group description
    		 Brexpiprazole was administered orally with flexible dosing from 2 to 4 milligrams (mg)/day; titrated to a maximum of 4 mg/day.

    Reporting group title
    Placebo
    Reporting group description
    		 Matching placebo was administered orally in the same way as brexpiprazole to maintain the blind.

    Reporting group values
    		 Brexpiprazole Placebo Total
    Number of subjects
    		 158 164 322
    Age categorical
    Units:
    Age continuous
    Units: Years
        arithmetic mean (standard deviation)
    		 43.4 ± 11.7 44.5 ± 11.2 -
    Gender categorical
    Units: Subjects
        Female
    		 80 83 163
        Male
    		 78 81 159
    Race/Ethnicity, Customized
    Units: Subjects
        Hispanic or Latino
    		 16 22 38
        Not Hispanic or Latino
    		 141 141 282
        Unknown
    		 0 1 1
        Ethnicity - Other
    		 1 0 1
    Race/Ethnicity, Customized
    Units: Subjects
        White
    		 95 113 208
        Black or African American
    		 54 51 105
        American Indian or Alaska Native
    		 2 0 2
        Asian
    		 3 0 3
        Native Hawaiian or Other Pacific Islander
    		 2 0 2
        Race - Other
    		 2 0 2

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    Brexpiprazole
    Reporting group description
    		 Brexpiprazole was administered orally with flexible dosing from 2 to 4 milligrams (mg)/day; titrated to a maximum of 4 mg/day.

    Reporting group title
    Placebo
    Reporting group description
    		 Matching placebo was administered orally in the same way as brexpiprazole to maintain the blind.

    Primary: Change From Baseline In Young-Mania Rating Scale (YMRS) Score At Week 3

    		 Close Top of page
    End point title
    		 Change From Baseline In Young-Mania Rating Scale (YMRS) Score At Week 3
    End point description
    The YMRS was utilized to assess a participant's level of manic symptoms. It consists of 11 items: 1) elevated mood, 2) increased motor activity-energy, 3) sexual interest, 4) sleep, 5) irritability, 6) speech (rate and amount), 7) language-thought disorder, 8) content, 9) disruptive-aggressive behavior, 10) appearance, and 11) insight. Seven items are rated on a 0- to 4-scale, while four items (Items 5, 6, 8, and 9) are rated on a 0- to 8-scale with 0, 2, 4, 6, and 8 being the possible scores (twice the weight of the other items). For all items, 0 is the “best” rating and the highest score (4 or 8) is the ‘worst’ rating. The YMRS total score is the sum of ratings for all 11 items; therefore, possible total scores range from 0 to 60, with higher scores signifying more severe manic symptoms. Comparison between treatment groups was carried out using mixed-effect model repeated measure (MMRM).
    End point type
    Primary
    End point timeframe
    Baseline, Week 3
    End point values
    		 Brexpiprazole Placebo
    Number of subjects analysed
    124 [1]
    134 [2]
    Units: units on a scale
        least squares mean (standard error)
    -10.6 ± 0.72
    -10.8 ± 0.70
    Notes
    [1] - Participants who had analyzable data at the specified timepoint.
    [2] - Participants who had analyzable data at the specified timepoint.
    Statistical analysis title
    		 Treatment Difference in YMRS
    Comparison groups
    Brexpiprazole v Placebo
    Number of subjects included in analysis
    258
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.8797
    Method
    		 Mixed-effect Model Repeated Measure
    Parameter type
    		 Treatment difference
    Point estimate
    0.14
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -1.74
         upper limit
    		 2.03

    Secondary: Change From Baseline In Clinical Global Impression-Bipolar (CGI-BP) Severity Score In Mania At Week 3

    		 Close Top of page
    End point title
    		 Change From Baseline In Clinical Global Impression-Bipolar (CGI-BP) Severity Score In Mania At Week 3
    End point description
    The CGI-BP scale refers to the global impression of the participant with respect to bipolar disorder. The scale rates the participant’s severity of illness (CGI-BP severity of illness: mania, depression, and overall bipolar illness) based on a 7-point scale: 1 = normal, not at all ill, 2 = minimally ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = very severely ill.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 3
    End point values
    		 Brexpiprazole Placebo
    Number of subjects analysed
    124 [3]
    134 [4]
    Units: units on a scale
        arithmetic mean (standard deviation)
    -1.12 ± 1.06
    -1.21 ± 1.13
    Notes
    [3] - Participants who had analyzable data at the specified timepoint.
    [4] - Participants who had analyzable data at the specified timepoint.
    No statistical analyses for this end point

    Adverse events

    		 Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From Day 1 (after dosing) through 6 weeks (3 weeks treatment, 3 weeks safety follow-up).
    Assessment type
    		 Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    21.1
    Reporting groups
    Reporting group title
    Brexpiprazole
    Reporting group description
    		 Brexpiprazole was administered orally with flexible dosing from 2 to 4 milligrams (mg)/day; titrated to a maximum of 4 mg/day.

    Reporting group title
    Placebo
    Reporting group description
    		 Matching placebo was administered orally in the same way as brexpiprazole to maintain the blind.

    Serious adverse events
    		 Brexpiprazole Placebo
    Total subjects affected by serious adverse events
         subjects affected / exposed
    4 / 158 (2.53%)
    1 / 163 (0.61%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    0
    0
    Nervous system disorders
    Akathisia
         subjects affected / exposed
    1 / 158 (0.63%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Dystonia
         subjects affected / exposed
    1 / 158 (0.63%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Thrombocytopenia
         subjects affected / exposed
    1 / 158 (0.63%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Psychiatric disorders
    Mania
         subjects affected / exposed
    1 / 158 (0.63%)
    1 / 163 (0.61%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Varicella
         subjects affected / exposed
    1 / 158 (0.63%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 3%
    Non-serious adverse events
    		 Brexpiprazole Placebo
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    20 / 158 (12.66%)
    24 / 163 (14.72%)
    Nervous system disorders
    Akathisia
         subjects affected / exposed
    8 / 158 (5.06%)
    2 / 163 (1.23%)
         occurrences all number
    8
    2
    Headache
         subjects affected / exposed
    6 / 158 (3.80%)
    11 / 163 (6.75%)
         occurrences all number
    8
    11
    Gastrointestinal disorders
    Constipation
         subjects affected / exposed
    2 / 158 (1.27%)
    6 / 163 (3.68%)
         occurrences all number
    2
    6
    Nausea
         subjects affected / exposed
    4 / 158 (2.53%)
    5 / 163 (3.07%)
         occurrences all number
    4
    6
    Psychiatric disorders
    Agitation
         subjects affected / exposed
    1 / 158 (0.63%)
    5 / 163 (3.07%)
         occurrences all number
    1
    5

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    21 Dec 2017
    • Removed an incorrect exclusion criteria of ≥ 30% decrease in YMRS between screening and baseline. • Added clarifying details on administration of the Clinical Global Impressions – Bipolar Scale assessment. • Added information on retesting participants with elevated lithium, valproate, or carbamazepine at screening. • Added information on use of anticholinergics. • Updated the efficacy scales in the appendices to match the licensed versions currently available.

    Interruptions (globally)
    Were there any global interruptions to the trial? No

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Apr 25 00:37:45 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA